DCT

3:20-cv-00787

Janssen Products LP v. Zydus Pharma USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:20-cv-00787, D.N.J., 01/23/2020
  • Venue Allegations: Plaintiff alleges venue is proper for Defendant Zydus USA as it is a New Jersey corporation with a regular and established place of business in the district. Venue over Defendant Cadila Healthcare is alleged on the basis that, as a foreign corporation, it may be sued in any judicial district.
  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic versions of the HIV protease inhibitor PREZISTA® (darunavir) constitutes an act of infringement of four U.S. patents covering pseudopolymorphic forms of the drug and methods of its preparation.
  • Technical Context: The technology relates to specific crystalline forms (solvates and hydrates) of the active pharmaceutical ingredient darunavir, which are important for ensuring the drug's stability, manufacturability, and bioavailability.
  • Key Procedural History: This is a Hatch-Waxman action initiated within 45 days of Plaintiff's receipt of Defendants' Paragraph IV Notice Letter. The complaint notes that the asserted patents have been the subject of numerous prior infringement litigations against other generic manufacturers, which resulted in consent judgments in Plaintiff's favor.

Case Timeline

Date Event
2001-09-10 ’015 Patent Priority Date
2002-05-16 ’645 and ’987 Patents Priority Date
2004-03-31 ’408 Patent Priority Date
2006-10-24 U.S. Patent No. 7,126,015 Issues
2009-09-29 U.S. Patent No. 7,595,408 Issues
2010-04-20 U.S. Patent No. 7,700,645 Issues
2013-08-27 U.S. Patent No. 8,518,987 Issues
2019-12-17 Plaintiff receives Defendants’ Paragraph IV Notice Letter
2020-01-23 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,700,645 - "Pseudopolymorphic forms of a HIV protease inhibitor," issued April 20, 2010

The Invention Explained

  • Problem Addressed: The patent's background describes the technical challenges in developing a new drug substance for commercial use, including ensuring its chemical purity, stability during storage, and consistent bioavailability for patients (US 7700645 Patent, col. 1:52-col. 2:20).
  • The Patented Solution: The invention claims specific "pseudopolymorphic forms" of the HIV protease inhibitor darunavir, which is the active ingredient in PREZISTA®. These forms are solvates, where solvent molecules (such as ethanol) are incorporated into the drug's crystal lattice. The patent asserts these specific solvate forms are stable, can be manufactured with high purity, and are suitable for pharmaceutical formulations (’645 Patent, Abstract; col. 2:50-67). Figure 4 of the patent illustrates the molecular structure of the darunavir compound within the crystal structure (’645 Patent, Fig. 4).
  • Technical Importance: Identifying a stable, crystalline form of an active pharmaceutical ingredient is a critical step in drug development, as it directly impacts manufacturing consistency, shelf-life, and the drug's performance in the body (’645 Patent, col. 2:5-20).

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims without specifying which ones (Compl. ¶86). Independent claim 1 is representative of the invention's scope.
  • Claim 1 Elements:
    • An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[(4-aminophenyl)sulfonylamino]-1-benzyl-2-hydroxypropylcarbamate,
    • in which the ratio of compound to ethanol is about 1:1.

U.S. Patent No. 8,518,987 - "Pseudopolymorphic forms of a HIV protease inhibitor," issued August 27, 2013

The Invention Explained

  • Problem Addressed: Similar to the ’645 Patent, this patent addresses the need for stable and manufacturable solid forms of the darunavir compound for use in pharmaceutical products (US 8518987 Patent, col. 1:52-col. 2:20).
  • The Patented Solution: This patent, from the same family as the ’645 patent, claims different pseudopolymorphic forms of darunavir. Specifically, it is directed to hydrates, where water molecules are incorporated into the crystal lattice, as opposed to the organic solvates of the ’645 patent. The patent provides data characterizing these hydrate forms, suggesting their suitability for pharmaceutical use (’987 Patent, Abstract; col. 3:24-30).
  • Technical Importance: Hydrates are a common solid form for pharmaceutical compounds and can offer distinct advantages in stability and handling properties compared to anhydrous or other solvate forms (’987 Patent, col. 2:5-20).

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims without specifying which ones (Compl. ¶94). Independent claim 1 is representative.
  • Claim 1 Elements:
    • A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(4-aminophenyl)sulfonylamino]-1-benzyl-2-hydroxypropylcarbamate
    • in which the ratio of the compound to water is about 1:0.5 to about 1:3.

Multi-Patent Capsule: U.S. Patent No. 7,126,015 ("’015 Patent")

  • Patent Identification: U.S. Patent No. 7,126,015, "Method for the Preparation of Hexahydro-furo-[2,3-b]furan-3-ol," issued October 24, 2006.
  • Technology Synopsis: The patent addresses the problem that prior art methods for synthesizing hexahydro-furo[2,3-b]furan-3-ol, a key chemical intermediate for darunavir, were not amenable to industrial scale-up due to expensive or dangerous reagents (US 7126015 Patent, col. 2:1-15). The invention provides a novel, stereoselective synthetic process that is suitable for large-scale industrial production (’015 Patent, Abstract; col. 2:26-34).
  • Asserted Claims: The complaint alleges infringement of one or more claims (Compl. ¶104).
  • Accused Features: Plaintiff alleges that Defendants' process for manufacturing the bis-THF intermediate, which is an essential component of the final darunavir drug substance, will infringe the claimed method (Compl. ¶¶ 54, 57, 104).

Multi-Patent Capsule: U.S. Patent No. 7,595,408 ("’408 Patent")

  • Patent Identification: U.S. Patent No. 7,595,408, "Method for the Preparation of (3R,3aS,6aR) Hexhydro-furo[2,3-b]furan-3-ol," issued September 29, 2009.
  • Technology Synopsis: This patent also relates to a process for preparing the bis-THF intermediate for darunavir. It identifies limitations in prior methods, including the Knoevenagel route's low yield and difficult work-up, and seeks to provide a more efficient and higher-yielding process (US 7595408 Patent, col. 2:1-60). The invention discloses an improved Wittig process that produces a key precursor in a methyl acetal form, which surprisingly can be crystallized to high purity, enabling higher overall yields (’408 Patent, col. 3:1-9; col. 4:5-13).
  • Asserted Claims: The complaint alleges infringement of one or more claims (Compl. ¶114).
  • Accused Features: As with the ’015 Patent, Plaintiff alleges that the manufacturing process used by Defendants for the bis-THF component of their generic darunavir product will infringe claims of the ’408 Patent (Compl. ¶¶ 54, 57, 114).

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are the generic darunavir 75 mg, 150 mg, 600 mg, and 800 mg tablets for which Defendants seek FDA approval via Abbreviated New Drug Application (ANDA) No. 214085 (the "ANDA Products") (Compl. ¶2).

Functionality and Market Context

The ANDA Products are intended to be generic versions of Janssen's PREZISTA®, an HIV protease inhibitor used for the treatment of HIV infections (Compl. ¶¶ 2, 44). The complaint characterizes PREZISTA® as "highly successful," suggesting a significant commercial market for the accused generic products (Compl. ¶2). The complaint alleges that the bis-THF component, made by the allegedly infringing processes, is an essential component of the final darunavir active pharmaceutical ingredient (API) in the ANDA Products (Compl. ¶¶ 54, 59).
No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges infringement based on "information and belief," stating that Defendants' refusal to provide technical details of their ANDA Products and manufacturing processes is consistent with infringement (Compl. ¶¶ 74, 104, 114).

7,700,645 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[(4-aminophenyl)sulfonylamino]-1-benzyl-2-hydroxypropylcarbamate... The API in the ANDA Products is alleged to be an ethanolate solvate of darunavir. ¶76 col. 2:50-53
...in which the ratio of compound to ethanol is about 1:1. The alleged ethanolate solvate in the ANDA Products' API has a stoichiometric ratio of darunavir to ethanol of approximately 1:1. ¶76 col. 29:3-7
  • Identified Points of Contention:
    • Factual Question: The central dispute will be factual: Does the darunavir API in the ANDA Products exist as an ethanolate solvate? This will likely require expert analysis using techniques like X-ray powder diffraction, which the patent uses for characterization (’645 Patent, Figs. 1-3).
    • Scope Question: What is the scope of the term "about 1:1"? The court's construction of this term will determine the range of stoichiometric ratios that fall within the claim.

8,518,987 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(4-aminophenyl)sulfonylamino]-1-benzyl-2-hydroxypropylcarbamate... The API in the ANDA Products is alleged to be a hydrate of darunavir. ¶76 col. 3:24-30
...in which the ratio of the compound to water is about 1:0.5 to about 1:3. The alleged hydrate form of the API in the ANDA Products contains a ratio of darunavir to water that falls within the range of approximately 1:0.5 to 1:3. ¶76 col. 31:11-15
  • Identified Points of Contention:
    • Factual Question: Similar to the '645 patent, the key issue is whether the API in the ANDA Products is a hydrate. This will depend on analytical evidence of water content and crystal structure.
    • Scope Question: How will the court construe the range "about 1:0.5 to about 1:3"? The interpretation of "about" will be critical to determining if the measured water content of the accused product infringes.

V. Key Claim Terms for Construction

For the lead patents, the dispute will likely focus on the characterization of the solid form.

  • The Term: "ethanolate solvate" (’645 Patent, Claim 1)

  • Context and Importance: The entire infringement theory for the ’645 Patent rests on whether the accused API is this specific type of solvate. Practitioners may focus on this term because its definition requires not just the presence of ethanol, but its incorporation into the crystal lattice in a defined structural relationship with the darunavir molecule.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification broadly defines pseudopolymorphs as including solvates, which are crystal forms with solvent molecules incorporated in their lattice structures (’645 Patent, col. 3:45-51). This may support an argument that any form with crystallographically bound ethanol meets the definition.
    • Evidence for a Narrower Interpretation: The patent provides very specific characterization data for "Form A (1:1)," including a unique X-ray powder diffraction pattern (Fig. 1) and atomic coordinates (Table 2) (’645 Patent, col. 6:6-14). A defendant may argue that the term should be limited to a form exhibiting these precise physical characteristics.

  • The Term: "about 1:1" (’645 Patent, Claim 1) / "about 1:0.5 to about 1:3" (’987 Patent, Claim 1)

  • Context and Importance: The definition of "about" is a classic claim construction issue that determines the permissible deviation from the recited numerical values. Its scope will be critical for infringement, as a defendant's product may have a ratio close to, but not exactly, the claimed values.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The use of the word "about" itself implies a degree of numerical flexibility beyond the precise numbers recited.
    • Evidence for a Narrower Interpretation: The patents provide detailed examples with specific analytical results from techniques like thermogravimetry (TG) that measure solvent/water loss (’645 Patent, Ex. 4). A party may argue that the scope of "about" should be constrained by the degree of precision and variability demonstrated in these examples.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges inducement and contributory infringement for all four patents (Compl. ¶¶ 86, 94, 104, 114). The factual basis for intent appears to be Defendants' filing of the ANDA with the purpose of marketing a generic product for the same uses as PREZISTA®, coupled with their alleged collaboration and concert of action (Compl. ¶¶ 67, 70).
  • Willful Infringement: Willfulness is alleged for the ’015 and ’408 process patents (Compl. ¶¶ 106, 116). The allegations are based on Defendants' alleged pre-suit actual and constructive notice of the patents, supported by the extensive litigation history and consent judgments against other generic manufacturers for infringing the same patents (Compl. ¶¶ 78, 105, 115).

VII. Analyst’s Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to two central factual questions that will require extensive discovery and expert testimony.

  • A core issue will be one of material composition: What is the precise solid-state crystalline form of the darunavir API in Defendants' ANDA Products? The answer will determine infringement of the ’645 and ’987 patents and will hinge on competing interpretations of analytical data from techniques like XRPD and thermal analysis.
  • A second core issue is one of manufacturing process: What is the actual synthetic pathway Defendants use to produce the key "bis-THF" intermediate for their darunavir API? This factual determination is necessary to assess infringement of the ’015 and ’408 process patents.
  • A key procedural question will be one of evidentiary access: The complaint repeatedly emphasizes Defendants' refusal to provide technical information. The case will likely feature significant discovery battles over the confidential contents of the ANDA and Drug Master File, the production of which will be essential for Plaintiff to attempt to prove its infringement allegations.
Loading Complaint